SSII
SS Innovations International, Inc.5.50
+0.41+8.06%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.06BP/E (TTM)
-Basic EPS (TTM)
-0.06Dividend Yield
0%Recent Filings
10-K
FY2025 results
SS Innovations doubled revenue to $42.5M in FY2025 ended December 31, 2025, with system sales surging to $38.4M from $19.5M y/y, fueled by 168 installed SSi Mantra systems (up from prior year) across India and 10 countries, enabling over 7,800 procedures. Gross profit jumped to $19.5M (46% margin), yet operating loss narrowed to $8.2M from $19.0M amid lower stock comp and scaled sales. Q4 momentum shone via SSi Mantra 3 launch, telesurgery approvals, and FDA 510(k) submission. Cash hit $9.6M after $28M principal shareholder notes; working capital swelled to $22.6M. No annual guidance disclosed. U.S. tariff policies threaten imports post-approval.
8-K
Revenue doubles; installs soar
SS Innovations blasted Q4 revenue to $14.5M, up 79.1% from $8.1M, with full-year sales doubling to $42.5M on 103 SSi Mantra installs—119% growth. Gross margins hit 46%, yet net loss widened to $12.1M amid heavy R&D and expansion spend. Debt-free with $3.2M cash, they just raised $18.6M in stock. FDA review eyes mid-2026.
8-K
Closes $18.6M private placement
SS Innovations closed a private placement on March 6, 2026, raising $18.6 million gross by issuing 5.8 million shares—$5.2 million at $4 average to insiders like CEO Srivastava, $13.4 million at $3 to investors led by Manipal. Funds fuel working capital, India growth, and U.S./EU prep, including FDA 510(k) review by mid-2026. Insiders bought in.
8-K
Q4 revenue up 85%
8-K
CFO resigns, Rao appointed COO/CFO
SS Innovations' CFO Naveen Kumar Amar resigned January 2, 2026, for personal reasons. Board appointed Milan Rao as new Global COO and CFO effective January 16 under a one-year services deal with $41,667 monthly pay and 120,000 vesting stock shares. Rao's three decades in healthcare ops promise scaling; yet services via his firm add consulting layer.
BSX
Boston Scientific Corporation
92.95+0.76
IART
Integra LifeSciences Holdings C
13.00-0.47
ISRG
Intuitive Surgical, Inc.
554.58-4.94
MBOT
Microbot Medical Inc.
2.22+0.01
RBOT
Vicarious Surgical Inc.
2.43-0.04
SGHT
Sight Sciences, Inc.
8.39+0.08
SIBN
SI-BONE, Inc.
19.42+1.01
STAA
STAAR Surgical Company
24.80+1.24
STXS
Stereotaxis, Inc.
2.38+0.06
SYK
Stryker Corporation
351.69-3.62